Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

The stock recently declined after the company released results from a Phase 3 trial of subcutaneous CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, which showed ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

The amycretin data look stronger than the 19% weight loss at 36 weeks generated for Lilly's own next-generation drug retatrutide in phase 2 (phase 3 data expected in 2026), and 20.4% cagrisema ...

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From a closing market price of $103.44 per share on December 19, 2024, Novo's ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.